Case report: Tisagenlecleucel for treatment of relapsed B- acute lymphoblastic leukemia in a patient with CHEK2 mutation

Case report: Tisagenlecleucel for treatment of relapsed B- acute lymphoblastic leukemia in a patient with CHEK2 mutation

BackgroundGermline Checkpoint Kinase 2 gene (CHEK2) mutations can increase the risk of solid tumors. Recently, they have been identified as risk factors for hematologic malignancies. However, to the best of our knowledge, B-acute lymphoblastic leukemia (B-ALL) has never been described as a presentin...

Full description

Bibliographic Details
Main Authors: Abraham Ipe, Anne Angiolillo, David Jacobsohn, Jinjun Cheng, Miriam Bornhorst, Joyce Turner, Anant Vatsayan
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Pediatrics
Subjects:
CAR-T
tisagenlecleucel
B-ALL
CHEK2 mutation
MDS
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2023.1067131/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2023.1067131/full

Similar Items